Calls for papers
-
Dance Biopharm has announced the appointment of former Dynavax chief medical officer and president J. Tyler Martin as President, a newly created position. Martin has also been appointed a member of the board of directors.… Read more . . .
-
Hosokawa Micron has introduced the Mini Cyclomix lab mixer for use in development of dry powder formulations for inhalation, the company announced. According to the company, the lab-sized blender is designed to disperse API in… Read more . . .
-
Theravance has announced that the the FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) and Drug Safety and Risk Management Advisory Committee will meet jointly on March 19, 2015 to discuss whether the Breo Ellipta fluticasone/vilanterol DPI… Read more . . .
-
GlaxoSmithKline and Theravance have announced the beginning of the FULFIL (Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy) Phase 3 study of a fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI in patients with… Read more . . .
-
DPI developer Respira Therapeutics has hired inhalation drug development pioneer Andy Clark as Vice President and Chief Technology Officer. Clark most recently served as Site Head and CTO at the Novartis pulmonary development facility in… Read more . . .
-
Lightlake Therapeutics has announced today that it has hired former Mundipharma Head of Medical Affairs for New Products Arvind Agrawal as Executive VP, Medical Affairs, effective January 2015. Agrawal has also held Medical Affairs positions… Read more . . .
-
Israeli biopharmaceutical company Advanced Inhalation Therapies (AIT) has announced that it received Orphan Drug Designation from the FDA last fall for its AIT-CF high dose nitric oxide formulation for the treatment of lung infections in… Read more . . .
-
Innovus Pharmaceuticals has announced that the acquisition of Novalere FP and its FlutiCare fluticasone propionate nasal spray. According to documents related to the merger filed with the US Securities and Exchange Commission (SEC), Novalere FP… Read more . . .
-
AstraZeneca will pay Actavis $600 million plus royalties for US and Canadian rights to Daliresp roflumilast and the Tudorza Pressair aclidinium bromide DPI, plus development rights to an aclidinium/formoterol DPI which was approved in Europe… Read more . . .
-
Oxford Lasers has announced the launch of its EnVision QC system for spray pattern and plume geometry testing of both MDIs and nasal sprays for quality control purposes. The Envision QC system includes automatic device… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland